Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned an average recommendation of "Buy" from the seven research firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $11.71.

RANI has been the topic of a number of research reports. HC Wainwright reduced their target price on shares of Rani Therapeutics from $13.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, August 16th. Oppenheimer started coverage on shares of Rani Therapeutics in a research note on Friday, August 2nd. They issued an "outperform" rating and a $17.00 price objective on the stock. Rodman & Renshaw started coverage on Rani Therapeutics in a research report on Thursday, June 13th. They set a "buy" rating and a $10.00 target price for the company. Finally, Maxim Group started coverage on Rani Therapeutics in a research report on Friday, June 14th. They issued a "buy" rating and a $15.00 price target on the stock.

Hedge Funds Weigh In On Rani Therapeutics

An institutional investor recently raised its position in Rani Therapeutics stock. Vanguard Group Inc. boosted its position in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) by 2.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 685,303 shares of the company's stock after buying an additional 16,956 shares during the period. Vanguard Group Inc. owned approximately 1.37% of Rani Therapeutics worth $2,131,000 at the end of the most recent quarter. Institutional investors own 30.19% of the company's stock.

Rani Therapeutics Price Performance

Shares of NASDAQ RANI traded down $0.16 during mid-day trading on Wednesday, hitting $2.46. 143,826 shares of the stock traded hands, compared to its average volume of 95,828. The company has a market cap of $124.03 million, a PE ratio of -1.91 and a beta of 0.16. Rani Therapeutics has a twelve month low of $1.82 and a twelve month high of $8.75. The company has a debt-to-equity ratio of 3.10, a current ratio of 1.93 and a quick ratio of 1.93. The firm has a 50 day simple moving average of $3.02 and a two-hundred day simple moving average of $4.08.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03. As a group, equities research analysts forecast that Rani Therapeutics will post -0.98 EPS for the current fiscal year.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.